Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

a™ involves the remodeling of the actin cytoskeleton (F-actin) of endothelial cells (cells that line the inside of blood vessels, including the retinal blood vessels) so that the adhesion molecules between these cells are tightly bound to the peripheral actin (cortical) resulting in tighter junctions among these cells, hence preventing vascular leakage from the blood compartment into tissue. The basic mechanism of action of Optina™ is described in a recently published manuscript entitled: "Biphasic effect of danazol on human vascular endothelial cell permeability and f-actin cytoskeleton dynamics" in Biochemical Biophysical Research Communications (BBRC 21 April 2012 http://dx.doi.org/10.1016/j.bbrc.2012.04.066). This is the first in a series of publications describing the biphasic effect of danazol on vascular permeability which is beneficial in reducing permeability (nano molar concentrations) and increasing permeability at the higher concentrations used in other approved indications (micro molar).

Dr. Vaughan Clift, Ampio's Chief Regulatory Officer, noted, "A clinical study of Optina™ for DME conducted in a double masked, placebo controlled manner at Saint Michael Hospital in Toronto, Canada, confirmed the in vitro findings that the ultra-low dose of danazol is beneficial while the high dose is detrimental. Complete analysis of the Optina™ trial is underway by our CRO and results will be published in the proper venues following a pre-IND meeting with the FDA. Ampio is preparing for a pre-IND meeting with the FDA to discuss plans for a pivotal trial(s) in the US under the 505(b)2 registration."

About Diabetic Retinopathy, Diabetic Macular Edema and current treatments
Diabetic retinopathy is damage to the retina of the eyes caused by complications of diabetes mellitus and often resulting in loss of visual acuity and blindness.  Macular edema of th
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne Medical Response, ... services, has been selected by Inc. Magazine as ... America. Photo - http://photos.prnewswire.com/prnh/20140914/145997 ... list identifies successful, privately-held companies with the largest ... Response, one of only two ambulance companies to ...
(Date:9/15/2014)... /PRNewswire-iReach/ -- CaPtivate Pharmaceuticals LLC, a ... (CaP)-based nanoparticle drug and vaccine delivery technologies, announced ... Agreement with Immunotope Inc., another Pennsylvania ... the treatment and prevention of viral infections and ... the agreement, Immunotope is granted a non-exclusive world-wide ...
(Date:9/15/2014)... The Society of Corporate Compliance and ... than 4,500 compliance and ethics professionals from across ... corporate fines and settlements.  The SCALENDAR is designed ... ready reference to demonstrate to employees the consequences ... to help compliance and ethics officers looking for ...
Breaking Medicine Technology:MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 2CaPtivate Pharmaceuticals Enters License Agreement With Immunotope 3More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2
... , WAYNE, N.J. and EMERYVILLE, Calif., Dec. ... Inc. (Nasdaq: ONXX ) today announced results ... 2 trials were presented at the 32nd Annual ... of these studies evaluated Nexavar® (sorafenib) tablets in ...
... , BATESVILLE, Ind., Dec. 11 Hill-Rom (NYSE: ... use in medical-surgical areas of hospitals and care facilities. The new bed ... to use a variety of care surfaces as needed. , "Hill-Rom ... the best features of Hill-Rom,s long-time leader, the Advanta bed, with many ...
Cached Medicine Technology:Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 2Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 3Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 4Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 5Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 6Nexavar in Combination With Chemotherapy Demonstrates Activity in Patients With Advanced Breast Cancer in Two Phase 2 Studies 7Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 2Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 3Hill-Rom Introduces Innovative Smart Bed for Medical-Surgical Settings 4
(Date:9/16/2014)... (PRWEB) September 16, 2014 ... information media site, launches their new site today. ... additional features aimed at making information easier to ... sift, we distill into one-page, easy-to-read pages the ... should know!” says Virginia Downie, retired college professor ...
(Date:9/16/2014)... 2014 The Living Ethics lecture series ... Reflecting on what it means to live in an ... unique and thought-provoking topics. , “The Museum’s job is ... look at their world differently. The Living Ethics ... for truly enlightening dialogue,” says Richard Conti, Chief Wonder ...
(Date:9/16/2014)... Banish headaches forever with the newest ... device for chronic migraine relief and treatment. Cefaly was ... States. Until now, US patients would directly place their ... and wait 2-3 weeks for their device to arrive. ... and once prescription and payment is received, the Cefaly ...
(Date:9/16/2014)... Recently, BamboofloorChina.com, a famous online supplier of bamboo products, ... bamboo panels . The firm is now offering ... its high quality items. Please note that the big ... 2014. , According to the company’s chief executive ... should visit BamboofloorChina.com before September 28. BamboofloorChina.com is offering ...
(Date:9/15/2014)... 16, 2014 Career Step, an ... training, is pleased to announce that Panacea Healthcare ... PCS comprehensive skill assessments and the ICD-10-CM and ... and Panacea’s consulting division. , “We are excited ... ICD-10 to our clients,” said Suzanne Lappen, Panacea ...
Breaking Medicine News(10 mins):Health News:JustThoughtYouShouldKnow.org Debuts New Website 2Health News:Expanding Community Vision at the Science Museum of Virginia 2Health News:Cefaly Migraine Treatment Device Now Readily Available For Widespread Purchase in United States 2Health News:Cheap Bamboo Panels Unveiled By Famous Online Supplier BamboofloorChina.com 2Health News:Panacea Healthcare Solutions to Resell Career Step’s ICD-10-CM and PCS Assessments and Case Studies 2Health News:Panacea Healthcare Solutions to Resell Career Step’s ICD-10-CM and PCS Assessments and Case Studies 3
... more attention be paid after hospital discharge, , , MONDAY, ... the veterans treated in Veterans Affairs hospitals suffer from ... suicide than non-depressed veterans, University of Michigan researchers report. ... and might it be related to their use of ...
... conjunction with its fourth quarter 2008 earnings release (expected to be issued after ... is pleased to invite you to listen to its quarterly investor conference call ... at 9:00 a.m. ET., What: Covance Fourth ... Presentation, When: ...
... Outdoor Recreation Participation StudyFindings include increase in overall ... The Outdoor Foundation today announced the ... Report, the only detailed study of its ... The findings highlighted in the report are areas ...
... Club is hosting a,Pharmacy Challenge and Savings Checkup in ... check prices on their prescriptions and,over-the-counter medications against other ... on branded prescriptions. Membership is not,required to use ... "Your Healthy Year" promotes a variety of ways consumers ...
... FRANCISCO, Jan. 12 Within health care, dermatology,professionals play ... , The Dermatology Nurses, Association ... practice in a variety,of learning formats and the opportunity ... annual conference slated for March,4-7 at the Hilton San ...
... CYBX ) today announced that Milton ... Research and Development, effective on January 12, 2009. ... company,s development programs. Dr. Morris joins Cyberonics from ... company in North Carolina, where he has served ...
Cached Medicine News:Health News:With Depression, Vets Face Higher Suicide Risk 2Health News:With Depression, Vets Face Higher Suicide Risk 3Health News:As Childhood Obesity Rates Rise, Youth Outdoor Participation Declines 2Health News:As Childhood Obesity Rates Rise, Youth Outdoor Participation Declines 3Health News:Sam's Club(R) Hosts Pharmacy Challenge 2Health News:Hop the Trolley for DNA's 27th Annual Conference 2Health News:Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development 2Health News:Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development 3Health News:Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development 4
The ELISA test is used for detection and semi quantitation of igG antibodies to proteinase 3(PR3) in human sera, as an aid to the diagnosis is of Wegener's granulomatosis....
... Acolytes core technology relates to the ultrasensitive ... found in all living cells. ATP ... using bioluminescence. By coupling AK ... via extraction using antibody-coated beads, Acolyte can ...
... DYONICS POWERMAX Shaver Handpiece has 25% more ... standard Smith & Nephew handpiece providing optimal ... handling and reduced hand fatigue. ,The forward/reverse ... suction lever are all co-located to allow ...
... tailored to individual needs. The pump can ... Indeed a Shaver unit only is featured ... and handpiece.,The REVOLUTION shaver system features a ... progressive motor (up to 4.000 rpm). When ...
Medicine Products: